Market Overview:
The global nonalcoholic steatohepatitis (NASH) market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into obeticholic acid（OCA） and selonsertib. OCA dominates the NASH treatment market owing to its high efficacy in treating NASH patients. Selonsertib is also expected to grow at a high rate during the forecast period as it has shown promising results in clinical trials for treating NASH patients. On the basis of application, hospital pharmacy dominates the global nonalcoholic steatohepatitis (NASH) treatment market followed by online provider and retail pharmacy segments respectively. Growth in these segments can be attributed to increasing awareness about available treatments for NASH patients among healthcare professionals as well as consumers across different geographies.
 Industry Outlook.svg)
Product Definition:
Nonalcoholic steatohepatitis (NASH) is a type of liver disease that occurs in people who drink little or no alcohol. The main symptom of NASH is fat accumulation in the liver. NASH can lead to cirrhosis, a condition in which the liver becomes so damaged that it can no longer function properly.
Obeticholic acid（OCA）:
Obeticholic acid is a naturally occurring, non-toxic fatty acid that has antioxidant properties. It can be extracted from certain plants and used to treat cancer as well as in the treatment of diseases like Gout, arthritis and other inflammatory conditions.
Selonsertib:
Selonsertib (SHL) is a novel oral drug that is expected to be launched in the second half of 2019. It has been granted Fast Track Designation by U.S FDA and Orphan Drug Designation by EU’s medicines agency, EMA for the treatment of Nonalcoholic Steatohepatitis (NASH). Selonsertib is currently under phase II clinical trial for determining its safety and efficacy in treating NASH.
Application Insights:
The global nonalcoholic steatohepatitis (NASH) market by application is categorized into hospital pharmacy, online provider and retail pharmacy. Hospital pharmacies held the largest share of over 60% in 2017. This is due to factors such as high prevalence of NASH patients in hospitals globally coupled with rising awareness about the treatment options among these patients.
Online providers are anticipated to be the fastest-growing segment at a CAGR of XX% from 2018 to 2030 owing to factors such as increasing internet accessibility.
Regional Analysis:
North America was the largest regional market in 2017 owing to high incidence of NASH and rising prevalence of obesity. The U.S., which is the most developed country in North America, has a high prevalence rate of obesity (35%) and diabetes (8.3 million cases) among its population as well as an increasing aging population prone to various diseases including NASH-associated liver disease such as steatohepatitis, fibrosis, cirrhosis & hepatocellular carcinoma.
Asia Pacific is expected to be the fastest growing region over the forecast period due to presence of developing countries such China & India with large patient pool for nonalcoholic fatty liver disease treatment options along with other factors such cost effective treatment methods.
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Rising awareness about the disease among people
- Growing number of research and development activities for NASH treatment
- Increasing demand for better treatment options for NASH patients
- Technological advancements in the field of diagnosis and treatment of NASH
Scope Of The Report
Report Attributes
Report Details
Report Title
Nonalcoholic Steatohepatitis (NASH) Market Research Report
By Type
Obeticholic acid（OCA）, Selonsertib
By Application
Hospital Pharmacy, Online Provider, Retail Pharmacy
By Companies
AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Nonalcoholic Steatohepatitis (NASH) Market Report Segments:
The global Nonalcoholic Steatohepatitis (NASH) market is segmented on the basis of:
Types
Obeticholic acid（OCA）, Selonsertib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Online Provider, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
 Market Overview.svg)
Highlights of The Nonalcoholic Steatohepatitis (NASH) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Obeticholic acid（OCA）
- Selonsertib
- By Application:
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nonalcoholic Steatohepatitis (NASH) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nonalcoholic steatohepatitis (NASH) is a condition that affects the liver and can lead to cirrhosis. It is caused by excessive accumulation of fat in the liver cells, which can damage the organ.
Some of the major players in the nonalcoholic steatohepatitis (nash) market are AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nonalcoholic Steatohepatitis (NASH) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nonalcoholic Steatohepatitis (NASH) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nonalcoholic Steatohepatitis (NASH) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nonalcoholic Steatohepatitis (NASH) Market Size & Forecast, 2018-2028
4.5.1 Nonalcoholic Steatohepatitis (NASH) Market Size and Y-o-Y Growth
4.5.2 Nonalcoholic Steatohepatitis (NASH) Market Absolute $ Opportunity
Chapter 5 Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
5.2.1 Obeticholic acid（OCA）
5.2.2 Selonsertib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Online Provider
6.2.3 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Nonalcoholic Steatohepatitis (NASH) Analysis and Forecast
9.1 Introduction
9.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
9.6.1 Obeticholic acid（OCA）
9.6.2 Selonsertib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Online Provider
9.10.3 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Nonalcoholic Steatohepatitis (NASH) Analysis and Forecast
10.1 Introduction
10.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
10.6.1 Obeticholic acid（OCA）
10.6.2 Selonsertib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Online Provider
10.10.3 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
11.6.1 Obeticholic acid（OCA）
11.6.2 Selonsertib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Online Provider
11.10.3 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Nonalcoholic Steatohepatitis (NASH) Analysis and Forecast
12.1 Introduction
12.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
12.6.1 Obeticholic acid（OCA）
12.6.2 Selonsertib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Online Provider
12.10.3 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type
13.6.1 Obeticholic acid（OCA）
13.6.2 Selonsertib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Online Provider
13.10.3 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nonalcoholic Steatohepatitis (NASH) Market: Competitive Dashboard
14.2 Global Nonalcoholic Steatohepatitis (NASH) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Arena Pharmaceuticals
14.3.3 GSK
14.3.4 Novo Nordisk
14.3.5 Roche
14.3.6 Vivus
14.3.7 Arisaph Pharmaceuticals
14.3.8 Cempra Pharmaceuticals
14.3.9 Galectin Therapeutics
14.3.10 Galmed Pharmaceuticals
14.3.11 Genfit
14.3.12 Gilead
